Volume 12 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(1): 90-95
Liu Ying, Sun Liying, Zhu Zhijun, et al. Diagnosis and treatment of hepatic sinusoidal obstruction syndrome after liver transplantation: a single-center experience[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 90-95. doi: 10.3969/j.issn.1674-7445.2021.01.014
Citation: Liu Ying, Sun Liying, Zhu Zhijun, et al. Diagnosis and treatment of hepatic sinusoidal obstruction syndrome after liver transplantation: a single-center experience[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 90-95. doi: 10.3969/j.issn.1674-7445.2021.01.014
shu

Diagnosis and treatment of hepatic sinusoidal obstruction syndrome after liver transplantation: a single-center experience

doi: 10.3969/j.issn.1674-7445.2021.01.014

  • Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

More Information
  • Corresponding author: Sun Liying, E-mail:sunxlx@outlook.com
  • Received Date: 2020-09-10
    Available Online: 2021-01-19
  • Publish Date: 2021-01-19
    Abstract
  •   Objective  To summarize the incidence, diagnostic and therapeutic experience of hepatic sinusoidal obstruction syndrome (HSOS) after liver transplantation.  Methods  Clinical data of 4 patients with HSOS after liver transplantation were retrospectively analyzed. The incidence, clinical manifestations, imaging and pathological characteristics of HSOS after liver transplantation were collected, and the treatment methods and clinical outcomes of patients with HSOS were analyzed.  Results  The incidence of HSOS after liver transplantation was 0.8%(2/239), and the median time of onset was 4.5(1.7, 9.0) months after liver transplantation. The clinical manifestations of HSOS mainly included abdominal distension, ascites, hepatomegaly, increased bilirubin, and renal insufficiency in partial cases. Enhanced abdominal CT scan of 4 patients with HSOS showed uneven spot-like enhancement and the liver histopathological examination mainly showed the signs of hepatic sinusoidal dilatation complicated with congestion. Four patients were administered with an adjusted regime of immunosuppressant by replacing tacrolimus (Tac) with ciclosporin and adding anticoagulant therapy with warfarin. One patient received transjugular intrahepatic portosystemic shunt (TIPS). After treatment, the symptoms of 3 patients were completely relieved, and 1 patient died. One of the 3 surviving patients died from pulmonary infection and gastrointestinal bleeding.  Conclusions  HSOS is a rare and fatal complication after liver transplantation. Timely diagnosis and treatment can avoid the incidence of graft failure and improve clinical prognosis of the patients.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    TAKADA S, MIYASHITA T, YAMAMOTO Y, et al. Soluble thrombomodulin attenuates endothelial cell damage in hepatic sinusoidal obstruction syndrome[J]. In Vivo, 2018, 32(6):1409-1417. DOI: 10.21873/invivo.11393.
    [2]
    HIRATA M, TAJIMA H, MIYASHITA T, et al. Extravasated platelet aggregation in the livers of rats with drug-induced hepatic sinusoidal obstruction syndrome[J]. Mol Med Rep, 2017, 15(5):3147-3152. DOI: 10.3892/mmr.2017.6407.
    [3]
    MIYATA T, TAJIMA H, HIRATA M, et al. Phosphodiesterase Ⅲ inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space[J]. J Gastroenterol Hepatol, 2018, 33(4):950-957. DOI: 10.1111/jgh.14004.
    [4]
    SEBAGH M, AZOULAY D, ROCHE B, et al. Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation[J]. Liver Transpl, 2011, 17(7):798-808. DOI: 10.1002/lt.22282.
    [5]
    SHEN T, FENG XW, GENG L, et al. Reversible sinusoidal obstruction syndrome associated with tacrolimus following liver transplantation[J]. World J Gastroenterol, 2015, 21(20):6422-6426. DOI: 10.3748/wjg.v21.i20.6422.
    [6]
    LI L, DONG Y, LI RD, et al. Sinusoidal obstruction syndrome related to tacrolimus following liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(3):299-302. DOI: 10.1016/j.hbpd.2020.03.014.
    [7]
    KITAJIMA K, VAILLANT JC, CHARLOTTE F, et al. Intractable ascites without mechanical vascular obstruction after orthotopic liver transplantation: etiology and clinical outcome of sinusoidal obstruction syndrome[J]. Clin Transplant, 2010, 24(1):139-148. DOI:10.1111/j.1399-0012. 2009.00971.x.
    [8]
    CHOI JH, WON YW, KIM HS, et al. Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver[J]. Oncol Lett, 2016, 11(4):2861-2864. DOI: 10.3892/ol.2016.4286.
    [9]
    FAN CQ, CRAWFORD JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)[J]. J Clin Exp Hepatol, 2014, 4(4):332-346. DOI: 10.1016/j.jceh.2014.10.002.
    [10]
    YANG XQ, YE J, LI X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes[J]. World J Gastroenterol, 2019, 25(28):3753-3763. DOI: 10.3748/wjg.v25.i28.3753.
    [11]
    CORBACIOGLU S, JABBOUR EJ, MOHTY M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Biol Blood Marrow Transplant, 2019, 25(7):1271-1280. DOI: 10.1016/j.bbmt.2019.02.018.
    [12]
    ROEKER LE, KIM HT, GLOTZBECKER B, et al. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(1):137-144. DOI: 10.1016/j.bbmt.2018.07.039.
    [13]
    FARACI M, BERTAINA A, LUKSCH R, et al. Sinusoidal obstruction syndrome/veno-occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group[J]. Biol Blood Marrow Transplant, 2019, 25(2):313-320. DOI: 10.1016/j.bbmt.2018.09.027.
    [14]
    YANG M, RUAN J, FU PP, et al. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity[J]. Chem Biol Interact, 2016, 243:119-126. DOI: 10.1016/j.cbi.2015.09.011.
    [15]
    POLI E, KOUNIS I, GUETTIER C, et al. Post-liver transplantation sinusoidal obstruction syndrome with refractory ascites induced by mycophenolate mofetil[J]. Hepatology, 2020, 71(4):1508-1510. DOI: 10.1002/hep.30984.
    [16]
    WEBER NT, SIGAROUDI A, RITTER A, et al. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report[J]. BMC Nephrol, 2017, 18(1):360. DOI: 10.1186/s12882-017-0757-5.
    [17]
    MARÍN-GÓMEZ LM, ÁLAMO-MARTÍNEZ JM, SUÁREZ-ARTACHO G, et al. Is the sinusoidal obstructive syndrome post-liver transplantation a pathologic entity with a multifactorial etiology?[J]. Rev Esp Enferm Dig, 2015, 107(4):235-238.
    [18]
    VAISVILAS M, BUSECKAITE S, MICKEVICIUTE O, et al. High-dose methylprednisolone for the treatment of sinusoidal obstruction syndrome in adults[J]. Bone Marrow Transplant, 2018, 53(7):923-925. DOI: 10.1038/s41409-018-0087-7.
    [19]
    LIU F, RONG X, GUO H, et al. Clinical characteristics, CT signs, and pathological findings of pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study[J]. BMC Gastroenterol, 2020, 20(1):30. DOI: 10.1186/s12876-020-1180-0.
    [20]
    WANG D, LV W, ZHANG S, et al. Advances in the research on anticardiolipin antibody[J]. J Immunol Res, 2019:8380214. DOI: 10.1155/2019/8380214.
    [21]
    TANACAN A, BEKSAC MS, ORGUL G, et al. Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, and anticardiolipin antibody positivity on obstetrical complications and pregnancy outcomes[J]. Hum Antibodies, 2019, 27(2):135-141. DOI: 10.3233/HAB-180359.
    [22]
    TSUCHIMOTO A, MATSUKUMA Y, UEKI K, et al. Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia[J]. CEN Case Rep, 2019, 8(1):1-7. DOI: 10.1007/s13730-018-0354-x.
    [23]
    ANSARI M, PETRYKEY K, REZGUI MA, et al. Genetic susceptibility to hepatic sinusoidal obstruction syndrome in pediatric patients undergoing hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(5):920-927. DOI: 10.1016/j.bbmt.2019.11.026.
    [24]
    HUEZO-DIAZ CURTIS P, UPPUGUNDURI CRS, MUTHUKUMARAN J, et al. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation[J]. Pharmacogenomics J, 2018, 18(1):64-69. DOI: 10.1038/tpj.2016.65.
    [25]
    PATRONO D, MAROLA S, DAVID E, et al. Long-term outcome of veno-occlusive disease after liver transplant: a retrospective single-center experience[J]. Exp Clin Transplant, 2019, 17(2):214-221. DOI: 10.6002/ect.2017.0315.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (228) PDF downloads(25) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return